Track Record

We have done business with: • BD UKWe worked on the following products: • BD PhaSeal™ closed system transfer device for hazardous drug handling.We worked together on the following projects: 2016: In collaboration with BD UK we provided strategic advise during the “Roundtable: How safe do you feel in the administration of hazardous drugs?“ Amsterdam, The Netherlands. Results were published in: http://www.hospitalpharmacyeurope.com/

We have done business with: • Boehringer Ingelheim Netherlands and • Boehringer Ingelheim European Regional Operating UnitWe worked on the following products: • nintedanib (Vargatef®) • afatinib (Giotrif®)We worked together on the following projects:2013: In collaboration with Boehringer Ingelheim Netherlands we provided an in-company training about afatinib-associated mucocutaneous adverse events at the headquarter of Boehringer Ingelheim Netherlands in Alkmaar, The Netherlands.2015: In collaboration with Boehringer Ingelheim Netherlands we provided an in-Company Safety Profile Bootcamp about TKI-associated adverse events at the headquarter of Boehringer Ingelheim Netherlands in Alkmaar, The Netherlands.2015: In collaboration with Boehringer Ingelheim Netherlands we reviewed and edited the afatinib kit for healthcare professionals.2015/2016: In collaboration with Boehringer Ingelheim Netherlands we trained pulmonologists, pharmacists and nurses about “Adverse event management in the use of targeted therapies and angiogenesis inhibitors” on several locations throughout The Netherlands: 01-12-2015: Rotterdam 08-12-2015: Groningen 22-12-2015: Eindhoven 12-01-2016: Amsterdam 14-01-2016: Ulvenhout 26-01-2016: Zwolle 28-01-2016: Den Haag 04-02-2016: Vught 16-02-2016: Hengelo 24-05-2016: Groningen 05-07-2016: Amersfoort 07-07-2016: Rotterdam 06-09-2016: Nijmegen 08-09-2016: Arnhem 18-10-2016: Arnhem2016: In collaboration with Boehringer Ingelheim Netherlands we recorded a video series for physicians in Dutch about selected afatinib-associated adverse events: paronychia, maculopapular rash, oral complaints, and mushy stool & diarrhea.2016: In collaboration with Boehringer Ingelheim Netherlands we trained pulmonologists and nurse specialists about “Developments in Lung Cancer – Meet the Expert”. Duiven, The Netherlands.2016: In collaboration with Boehringer Ingelheim European Regional Operating Unit: we recorded a video series for internal training in English about selected nintedanib-associated adverse events: diarrhea, nausea, vomiting, loose of appetite, neutropenia and increased liver enzymes.

We have done business with: • BMS Netherlands.We worked on the following products: • nivolumab (Opdivo®)We worked together on the following projects:2016: In collaboration with BMS Netherlands we worked on the development of treatment guidelines about the management options for immune related adverse events and patient information nivolumab (Opdivo®).

We have done business with: • EUSA Pharma UK LtdWe worked on the following products: • supersaturated calcium-phosphate rinse (Caphosol®), a topical oral agent, is a US patented medical device that lubricates the mucosa of the mouth, tongue and oropharynx and helps maintain the integrity of the oral cavity through its mineralizing potential. The distinguishing feature of Caphosol® is its high concentrations of calcium and phosphate ions. • tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications. Tivozanib has been investigated in several tumours types, including renal cell, colorectal and breast cancers. EUSA Pharma have submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line treatment of advanced renal cell carcinoma (RCC) in March 2016.We worked together on the following projects:2012/2016 In collaboration with EUSA Pharma UK Ltd we worked on the Investigator Initiated COMTT trial. Eusa is an independent co-sponsor.2016: In collaboration with EUSA Pharma UK Ltd we provided an in-company training about “Tivozanib – Adverse Event Management following the steps of the TARGET system”.

We have done business with: • Galera Therapeutics Global.We worked on the following products: • GC4419, a first-in-class, small molecule enzyme mimetic that converts superoxide to hydrogen peroxide and molecular oxygen. GC4419 is currently being evaluated in an ongoing randomized Phase 2 clinical trial to assess its effect on the incidence, severity and duration of severe oral mucositis (OM) when given to patients with squamous cell cancers of the head and neck in combination with radiation and chemotherapy. GC4419 previously completed a Phase 1b/2a clinical trial and results were presented at the 2016 Annual Meeting of the American Society of Radiation Oncology (ASTRO). In this study, compared to historic controls, GC4419 appeared to: • Decrease severe OM incidence (WHO Grade 3+4) • Delay severe OM onset • Shorten severe OM duration • Lessen significant radiation therapy treatment breaks GC4419 was generally safe and well tolerated. Some patients experienced mild facial paresthesia. There was no evidence of tumor protection and the mechanism of action is thought to favor increasing tumor radiation response. GC4419 has received fast track designations from the U.S. Food and Drug Administration.We worked together on the following projects:2017: In collaboration with Galera Therapeutics Global we provided strategic advise during the Advisory Board about the treatment of radiation-induced mucositis, Barcelona, Spain.

We have done business with: • GSK NetherlandsWe worked on the following products: • lapatinib (Tykerb® (USA); Tyverb® (EU)), an orally active drug for patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2) and other solid tumours.We worked together on the following projects:2008: In collaboration with GSK Netherlands we provided strategic advise during the Expert Panel Member Meeting lapatinib, Utrecht, The Netherlands.2011: In collaboration with GSK Netherlands we reviewed and edited patient related material regarding lapatinib.2011: In collaboration with GSK Netherlands we provided an in-company training about adverse event management TKI’s with special attention on GSK’s lapatinib and pazopanib.2012/2013: In collaboration with GSK Netherlands we provided Assessment trainings mucocutaneous adverse events on several locations throughout The Netherlands.

We have done business with: • Helsinn GlobalWe worked on the following products: • netupitant (Netu; NKE; R 1124; Ro 67-3189/000) for pruritusWe worked together on the following projects: 2016: In collaboration with Helsinn Global we provided strategic advise during the “Helsinn Pruritus in Cancer Patients - International Multidisciplinary Experts Panel” Zurich, Switzerland

We have done business with: • Ipsen GlobalWe worked on the following products: • cabozantinib (Cabometyx®) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.We worked together on the following projects:2017: In collaboration with Ipsen Global we provided strategic advise during the “Optimising Patient Management Strategies in RCC: What Nurses Need to Know” for Medscape Oncology” Amsterdam, The Netherlands

Popup content

We have done business with: • Lifestream Pharma NV SA In conjunction with Caresse CosmeticsWe worked on the following products: • lactoperoxidase (BioXtra) dry mouth ultra-mild mouth rinse. BioXtra® provide four interrelated oral care products specially formulated to moisturize, comfort and protect the mouth, and to promote better oral hygiene. Reference. Lactoperoxidase is a peroxidase enzyme secreted from mammary, salivary, and other mucosal glands that functions as a natural antibacterial agent. Lactoperoxidase is a member of the heme peroxidase family of enzymes. In humans, lactoperoxidase is encoded by the LPO gene. Lactoperoxidase catalyzes the oxidation of a number of inorganic and organic substrates by hydrogen peroxide. These substrates include bromide and iodide and therefore lactoperoxidase can be categorized as a haloperoxidase. Another important substrate is thiocyanate. The oxidized products produced through the action of this enzyme have potent bactericidal activities. Lactoperoxidase together with its inorganic ion substrates, hydrogen peroxide, and oxidized products is known as the lactoperoxidase system. The lactoperoxidase system plays an important role in the innate immune system by killing bacteria in milk and mucosal (linings of mostly endodermal origin, covered in epithelium, which are involved in absorption and secretion) secretions hence augmentation of the lactoperoxidase system may have therapeutic applications. Furthermore, addition or augmentation of the lactoperoxidase system has potential applications in controlling bacteria in food and consumer health care products. The lactoperoxidase system does not attack DNA and is not mutagenic. However, under certain conditions, the lactoperoxidase system may contribute to oxidative stress. Furthermore, lactoperoxidase may contribute to the initiation of breast cancer, through its ability to oxidize estrogenic hormones producing free radical intermediates. BioXtra Dry Mouth Ultra Mild Mouth rinse gently supplements natural saliva by regulating the microenvironment of the mouth. The mild tasting formulation strengthens enamel, helps fight against the formation of dental caries and ease the symptoms and effects of Dry Mouth (xerostomia). It helps maintain the mouth’s natural balance and cleanse, refresh and lubricate your mouth. BioXtra Dry Mouth Ultra Mild Mouth rinse is alcohol and menthol free.We worked together on the following projects:2016/2017: In collaboration with Lifestream Pharma nv sa we trained nurses and physicians about the usage of the various kinds of products within immuno-oncology and targeted therapy treatment.

We have done business with: • Merck NetherlandsWe worked on the following products: • cetuximab (Erbitux®) • vitamin K1 creamWe worked together on the following projects:2006: In collaboration with Merck Netherlands we developed patient information/Fact sheets for treatment with cetuximab: dry skin, fissures, papulopustular rash and paronychia.2012: In collaboration with Merck Netherlands we provided strategic advise during the Scientific Advisory Board about Vitamin K.2012: In collaboration with Merck Netherlands we trained nurses about cetuximab-associated rash and Vitamin K cream.2014: In collaboration with Merck Netherlands we developed the research protocol and protocol-associated documentation for the ProSkin study - Prospective, observational practice survey of applied skin care and management of cetuximab related skin reactions: ProSkin Netherlands.2014: In collaboration with Merck Netherlands we trained nurses about cetuximab-associated skin reaction management.2015: In collaboration with Merck Netherlands we developed documentation for healthcare professionals: Skin reactions during treatment with cetuximab (Erbitux®).2015: In collaboration with Merck Netherlands we recorded a video for the Merck Family & Board. Video about the long-standing collaboration with Merck Netherlands.

We have done business with: • MSD Global • MSD Europe, and • MSD AustriaWe worked on the following products: • ridaforolimus (also known as AP23573 and MK-8669; formerly known as deforolimus), an investigational targeted and small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN known to be important to malignancy. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. It has had promising results in a clinical trial for advanced soft tissue and bone sarcoma.We worked together on the following projects:2011: In collaboration with MSD Global we provided strategic advise during the Global Oral Stomatitis Expert Input Forum in Lisbon, Portugal2012: In collaboration with MSD Global we provided strategic advise during the Jenzyl EU Train the Trainer in Lisbon, Portugal2012: In collaboration with MSD Europe we provided strategic advise during the Expert Meeting Stomatitis, Munich, Germany

We have done business with: • Nordic Pharma NetherlandsWe worked on the following products: • tegafur, gimeracil and oteracil (Teysuno®). It is available as capsules containing 15 mg tegafur with 4.35 mg gimeracil and 11.8 mg oteracil, and as capsules containing 20 mg tegafur with 5.8 mg gimeracil and 15.8 mg oteracil. Teysuno is used to treat adults with advanced gastric (stomach) cancer. It is used in combination with cisplatin. Tegafur is a ‘prodrug’ that is converted in the body to a chemical called 5-fluorouracil (5-FU). 5-FU is similar to pyrimidine, a substance found in the genetic material of cells (DNA and RNA). In the body, 5-FU takes the place of pyrimidine and interferes with the enzymes involved in making new DNA. As a result, it prevents the growth of cancer cells and eventually kills them. The two other active substances in Teysuno allow tegafur to be effective at lower doses and with fewer side effects: gimeracil by preventing the breakdown of 5-FU and oteracil by reducing the activity of 5-FU in normal, non-cancerous tissue in the gut.We worked together on the following projects:2014/2015: In collaboration with Nordic Pharma Netherlands: Training about the differences between hand-foot syndrome, hand-foot skin reaction, and peripheral neuropathy. In conjunction with a local medical oncologist, on several locations throughout The Netherlands.2017: In collaboration with Nordic Pharma Netherlands: Training about the differences between hand-foot syndrome, hand-foot skin reaction, peripheral neuropathy, and poorly treated feet. In conjunction with a local medical oncologist, on several locations throughout The Netherlands.

We have done business with: • Novartis Global, • Novartis Netherlands, • Novartis Italy, and • Novartis Belgium.We worked on the following products: • everolimus (Afinitor, Zortress, Afinitor Disperz®), an mTOR inhibitor/selective immunosuppressant is used in the treatment of brain tumor, breast cancer, neuroendocrine carcinoma, organ transplant, rejection prophylaxis, pancreatic cancer, renal angiomyolipoma, renal cell carcinoma, subependymal giant cell astrocytoma, and tuberous sclerosis. Reference.We worked together on the following projects:2008: In collaboration with Novartis Netherlands we provided strategic advise during the Round Table input everolimus. Utrecht, The Netherlands.2013: In collaboration with Novartis Global we provided strategic advise during the Advisory Board for Afinitor, Educational Needs. Chicago, USA.2013: In collaboration with Novartis Global we provided strategic advise during the Novartis Oncology Leader's Summit 2013. The annual events that focus on addressing unmet educational needs and fostering a collaborative multidisciplinary approach to breast cancer treatment. This year the latest advances in the management of hormone receptor-positive and/or HER2-positive advanced breast cancer. Multidisciplinary Centers for Excellence. Geneva, Switzerland.2014: In collaboration with Novartis Italy and in conjunction with COPE-unlimited we trained nurses at satellite symposium “Recent advances in oral targeted therapies in patients with solid tumors”. Istanbul, Turkey.2014: In collaboration with Novartis Netherlands and in conjunction with Eurocept Homecare we trained homecare nurses about “Metastatic breast cancer patients treated with everolimus”. Arnhem, The Netherlands.2015: In collaboration with Novartis Netherlands we trained nurse practitioners in a masterclass during the annual conference for nurse practitioners: “Master Scientific research in Oncology.” Papendal, The Netherlands.2015: In collaboration with Novartis Global we developed the Online Education Module For Nurses Only Program: Afinitor Video Project.2016: In collaboration with Novartis Belgium we trained medical oncologists and their team in an interdisciplinary workshop about Adverse Event Management. Oostkamp, Belgium.2017: In collaboration with Novartis Belgium we trained medical oncologists and their team in an interdisciplinary workshop about Adverse Event Management. Brugge, Belgium.

We have done business with: • Pfizer Netherlands and • Pfizer International Operations (S.A.S.) Medical Oncology Europe:We worked on the following products: • sunitinib (Sutent®) • axitinib (Inlyta®)We worked together on the following projects:2009: In collaboration with Pfizer Netherlands we trained physicians and nurses on Therapy management during treatment of metastatic renal cell carcinoma with targeted therapy. Chair. Amsterdam, The Netherlands.2011: In collaboration with Pfizer Netherlands and in conjunction with Curavista Health we built a Platform for patients with RCC: an online patient self-management diary to be completed by the patient, designed for patients with renal cell carcinoma.2012: In collaboration with Pfizer International Operations (S.A.S.) Medical Oncology Europe we updated the president of Pfizer Europe and his team about “Therapy Management Needs, Personalized Needs, Projects, Interdisciplinary Multinational Collaboration in Past, Now and Future. Amsterdam, The Netherlands.2013: In collaboration with Pfizer Netherlands we reviewed and edited the Patient information axitinib (Inlyta®).2014: In collaboration with Pfizer Netherlands we recorded videos about Dermatological & Oral Assessment for nurses and physicians in Dutch.2014: In collaboration with Pfizer Netherlands we developed an Online Education Module with a pre- and posttest for the face-to-face training “targeted therapy-associated mucocutaneous adverse events.” With this pre-and post-test participants were able to assess their knowledge progress.2015: In collaboration with Pfizer Netherlands we trained nurses about Therapy Management during sunitinib Treatment. Amsterdam, The Netherlands2015: In collaboration with Pfizer Netherlands we developed and provided a one-day (8 hours) in depth training about targeted therapy-associated mucocutaneous adverse events for nurses and pharmacists on several locations throughout The Netherlands.2016: In collaboration with Pfizer International Operations (S.A.S.) Medical Oncology Europe we provided strategic advise during the 3rd Onco Nurse Academy. Copenhagen, Denmark. Nurses from BeNeLux, Nordic and Baltic region, Belarus attended.2016: In collaboration with Pfizer Netherlands we developed and provided the interdisciplinary training “Management of targeted- & immunotherapy-associated skin, oral & mucosal reactions. Medical oncologists, pulmonologists, dermatologists, pharmacists, and nurse specialists attended the training and discussed during the training how to implement the effective adverse event approach in their daily practice. As an additional service, attendees received aftercare to support the implementation of the learned approach in day-to-day practice.2017: In collaboration with Pfizer Netherlands we developed and provided Immuno-Oncology Training of 3 hours together with a local physician (medical oncologist or pulmonologist)2017: In collaboration with Pfizer International Operations (S.A.S.) Medical Oncology Europe we provided strategic advise during the 4th Onco Nurse Academy. Copenhagen, Denmark.

We have done business with: • Roche NetherlandsWe worked on the following products: • capecitabine (Xeloda®) for breast and colorectal cancer • filgrastim (Neupogen®) for neutropenia • erlotinib (Tarceva®) • vemurafenib (Zelboraf®)We worked together on the following projects:2008: In collaboration with Roche Netherlands we were jury member of the Breast Friends Award 2008.2009: In collaboration with Roche Netherlands we were jury member of the Breast Friends Award 2009.2011: In collaboration with Roche Netherlands we reviewed and edited the patient brochure erlotinib (Tarceva®) for various cancers.2012: In collaboration with Roche Netherlands: we reviewed and edited the patient brochure vemurafenib (Zelboraf®) for late-stage V600E BRAF mutation-positive melanoma.2015: In collaboration with Roche Netherlands we generated an article, a SOS chart, and an assessment of signs & symptoms tool for EGFRI-associated mucocutaneous adverse events.2016: In collaboration with Roche Netherlands we developed the E-learning module “EGFR-inhibitor-associated adverse events in NSCLC”. In conjunction with e-WISE/CME Academy.

We have done business with: • Takeda Global and • Takeda NetherlandsWe worked on the following products: • fentanyl (Instanyl®). Instanyl is a nasal spray that contains the active substance fentanyl (50, 100 and 200 micrograms per dose). It is available in single-dose containers and in multidose containers. Instanyl is used to treat ‘breakthrough’ pain in adults with cancer. ‘Breakthrough pain’ is when a patient experiences additional, sudden pain in spite of ongoing treatment with painkillers. Instanyl is used in patients who are already using opioids to control long-term cancer pain.We worked together on the following projects:2014: In collaboration with Takeda Netherlands we provided strategic advise during the Interdisciplinary Advisory Oral Pain Management Forum2014: In collaboration with Takeda Netherlands we provided an in-company training in oral pain management.2014: In collaboration with Takeda Global we provided a presentation at the Meet-the-Experts session during 8th EAPC World Research Congress, Lleida, Spain: Title of the presentation: Dry mouth and swallowing issues in cancer patients on targeted therapies2014: In collaboration with Takeda Netherlands we trained homecare nurses about targeted therapy-associated oral complaints on several locations throughout The Netherlands.

Popup content

Interested in Dr. Christine Boers-Doets's approach? Then contact us at team@christineboersdoets.com

Interested in Dr. Christine Boers-Doets's approach? Then contact us at team@christineboersdoets.com